<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(1)</volume><submitter>Park HM</submitter><pubmed_abstract>RNA-protein interactions are crucial for diverse biological processes. In prokaryotes, RNA-protein interactions enable adaptive immunity through CRISPR-Cas systems. These defence systems utilize CRISPR RNA (crRNA) templates acquired from past infections to destroy foreign genetic elements through crRNA-mediated nuclease activities of Cas proteins. Thanks to the programmability and specificity of CRISPR-Cas systems, CRISPR-based antimicrobials have the potential to be repurposed as new types of antibiotics. Unlike traditional antibiotics, these CRISPR-based antimicrobials can be designed to target specific bacteria and minimize detrimental effects on the human microbiome during antibacterial therapy. In this study, we explore the potential of CRISPR-based antimicrobials by optimizing the RN</pubmed_abstract><journal>Biology direct</journal><pagination>27</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9547417</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>In silico optimization of RNA-protein interactions for CRISPR-Cas13-based antimicrobials.</pubmed_title><pmcid>PMC9547417</pmcid><pubmed_authors>De Neve W</pubmed_authors><pubmed_authors>Park Y</pubmed_authors><pubmed_authors>Vankerschaver J</pubmed_authors><pubmed_authors>Berani U</pubmed_authors><pubmed_authors>Bang E</pubmed_authors><pubmed_authors>Park HM</pubmed_authors><pubmed_authors>Shim H</pubmed_authors><pubmed_authors>Van Messem A</pubmed_authors></additional><is_claimable>false</is_claimable><name>In silico optimization of RNA-protein interactions for CRISPR-Cas13-based antimicrobials.</name><description>RNA-protein interactions are crucial for diverse biological processes. In prokaryotes, RNA-protein interactions enable adaptive immunity through CRISPR-Cas systems. These defence systems utilize CRISPR RNA (crRNA) templates acquired from past infections to destroy foreign genetic elements through crRNA-mediated nuclease activities of Cas proteins. Thanks to the programmability and specificity of CRISPR-Cas systems, CRISPR-based antimicrobials have the potential to be repurposed as new types of antibiotics. Unlike traditional antibiotics, these CRISPR-based antimicrobials can be designed to target specific bacteria and minimize detrimental effects on the human microbiome during antibacterial therapy. In this study, we explore the potential of CRISPR-based antimicrobials by optimizing the RN</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2026-05-31T16:05:19.863Z</modification><creation>2025-02-19T01:27:44.552Z</creation></dates><accession>S-EPMC9547417</accession><cross_references><pubmed>36207756</pubmed><doi>10.1186/s13062-022-00339-5</doi></cross_references></HashMap>